Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumours in cell culture.
Human pancreatic growth hormone releasing factors (hpGRF(1-40) and hpGRF(1-44) significantly stimulated GH secretion when added to cell cultures of human somatotrophic pituitary tumours for 2 h. There was little difference in potency between the two peptides, and the response of different tumours varied, ranging from 30% to 500% increases in GH secretion over control levels. This stimulatory effect was blocked by somatostatin (SRIF) and bromocriptine. The suppressive effect of bromocriptine, but not of SRIF, was overcome by high doses of hpGRF(1-44). TRH stimulated GH secretion by one of three somatotrophic tumours in cell culture, and it was found to potentiate the stimulatory effects of hpGRF(1-44). These results demonstrate that hpGRFs increase serum GH levels in man by a direct action at the pituitary somatotroph level.
D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology; D002478:Cells, Cultured; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000494:pharmacology*; D010911:Pituitary Neoplasms / Q000378:metabolism*; D012636:Secretory Rate / Q000187:drug effects; D013004:Somatostatin / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D010446:Peptide Fragments; C036893:somatotropin releasing factor 40; D001971:Bromocriptine; D013004:Somatostatin; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone